AeroVanc: Phase II data

A double-blind, U.S. Phase II trial in 87 CF patients with persistent MRSA lung infection showed that twice-daily inhaled AeroVanc met the primary endpoint

Read the full 249 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE